In a 14‑week pregnant patient with hyperthyroidism presenting with diarrhea, what is the appropriate management?

Management of Hyperthyroidism with Diarrhea at 14 Weeks Pregnancy

At 14 weeks gestation, you should immediately switch from propylthiouracil (PTU) to methimazole (MMI) if the patient is currently on PTU, as the critical first-trimester teratogenic window has passed, and PTU carries significant hepatotoxicity risk beyond the first trimester. 1, 2

Immediate Thyroid Management

Antithyroid Drug Strategy

The patient is now in the second trimester (14 weeks), which fundamentally changes the antithyroid drug approach:

• Switch to methimazole if currently on PTU. The first trimester (when MMI embryopathy risk is highest) has passed, and continuing PTU beyond this point exposes the patient to severe hepatotoxicity risk 1, 2
• Use the lowest effective dose to maintain free T4 in the upper one-third of the trimester-specific reference range 1, 3
• Avoid block-and-replace therapy (combining antithyroid drugs with levothyroxine) as levothyroxine crosses the placenta poorly; use adapted-dose monotherapy only 2

Important caveat: When switching medications during pregnancy, thyroid balance can destabilize—you must increase monitoring frequency to every 2-4 weeks initially 2.

Treatment Targets

• Aim for subclinical hyperthyroidism (slightly suppressed TSH with free T4 in upper-normal pregnancy range)
• Measure TSH, free T4, and total T3 levels 1
• Use pregnancy-specific reference ranges, not standard non-pregnant values 1

Managing the Diarrhea

Beta-Blocker Therapy

Add propranolol or metoprolol for symptomatic control of diarrhea, which is a manifestation of thyrotoxicosis mediated through sympathetic activation 4:

• Beta-blockers effectively slow intestinal transit time and control hyperthyroidism-associated diarrhea 4
• This provides rapid symptomatic relief while waiting for antithyroid drugs to achieve euthyroidism
• Metoprolol is specifically mentioned as acceptable in pregnancy with obstetrical agreement 1
• Beta-blockers should be used short-term for symptom control, not as primary therapy 1

Pathophysiology Context

The diarrhea in hyperthyroidism can be either:

• Secretory diarrhea from increased intestinal motility (most common)
• Steatorrhea from bile acid malabsorption 4

Both respond to beta-adrenergic blockade by reducing sympathetic stimulation of the gastrointestinal tract 4.

Monitoring Protocol

Frequent monitoring is critical given the medication switch and need to prevent both maternal thyrotoxicosis and fetal hypothyroidism:

• Every 2-4 weeks initially after switching to MMI 2
• Measure TSH, free T4, and total T3 each visit 1
• Monitor for signs of overtreatment (which causes fetal hypothyroidism) or undertreatment (which causes maternal complications and central congenital hypothyroidism) 1

Maternal and Fetal Risk Assessment

Inadequately treated hyperthyroidism carries severe risks 1:

• Preterm delivery
• Intrauterine growth restriction and low birth weight
• Pre-eclampsia
• Congestive heart failure
• Fetal death

Check TRAb (TSH receptor antibodies) if not already done, as levels >3 times upper normal limit can cause fetal hyperthyroidism requiring maternal treatment 1.

What NOT to Do

• Do not use radioactive iodine—absolutely contraindicated 2, 5
• Do not continue PTU beyond first trimester unless there are compelling reasons (severe allergy to MMI, or if hyperthyroidism is so well-controlled that treatment may be discontinued soon) 2
• Do not add levothyroxine to the antithyroid drug regimen 2
• Do not aim for complete TSH normalization—slight suppression is acceptable to minimize fetal drug exposure 1

Surgery Consideration

Thyroidectomy is reserved only for:

• Severe allergy to both antithyroid drugs
• Poor control despite maximum medical therapy
• If needed, perform during second trimester (ideally weeks 14-24) 2

This patient at 14 weeks is at the earliest acceptable window for surgery if medical management fails.